Status:
COMPLETED
Evaluation of Retinal and Vascular Features in Radiation Maculopathy After Intravitreal Injections of Ranibizumab
Lead Sponsor:
Federico II University
Conditions:
Radiation Maculopathy
Eligibility:
All Genders
40-60 years
Brief Summary
This study evaluates the retinal and vascular features in patients with radiation maculopathy under the effects of Ranibizumab intravitreal injections using optical coherence tomography and optical co...
Detailed Description
The radiation maculopathy is a consequence of radiotherapy for treatment of choroidal melanoma. The radiation maculopathy is characterized by the compromission of the macular microvasculature that can...
Eligibility Criteria
Inclusion
- age older than 40 years
- diagnosis of radiation maculopathy
- treatment-naïve with Ranibizumab
- absence of other vitreoretinal and vascular retinal diseases
Exclusion
- age younger than 40 years
- No diagnosis of radiation maculopathy
- previous treatments with Ranibizumab
- presence of vitreoretinal and vascular retinal diseases
Key Trial Info
Start Date :
October 30 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 30 2019
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04377295
Start Date
October 30 2012
End Date
October 30 2019
Last Update
May 6 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.